~~<i id='61383D029C'><strike id='61383D029C'><tt id='61383D029C'><pre id='61383D029C'></pre></tt></strike></i>~~

Home» focus» explore

explore

author：hotspot 2025-08-15 09:11:56 Page View：8

Neumora, a neuroscience startup founded by VC Arch Venture Partners, hopes to become one of the few biotechs to go public this year.

The company filed paperwork for an IPO with the Securities and Exchange Commission on Friday. It did not state how many shares it plans to sell or at what price.

The biotech had begun planning for an IPO last year, STAT reported in June 2022. It raised $112 million in what would turn out to be a crossover round last October.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Readout LOUD podcast: Live from STAT Breakthrough Summit West
Next article： Supreme Court strikes down use of affirmative action

explore

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Can we make enough H5N1 bird flu vaccine if there's a pandemic?

Illustration:ChristineKao/STAT;Photos:GettyTheunsettlingrealityofH5N1birdflucirculatingindairycowher

DIEP, the 'gold standard' of breast reconstruction, is under threat

AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

Why Novartis is going to walk from its acquisition of MorphoSys

MollyFerguson/STATNovartissaidMondaythatitintendstobuyMorphoSysforjustunder$3billion.Thedealwillnotc